ReElement Technologies stock soars after securing $1.4B government deal
Investing.com - BTIG lowered its price target on Tvardi Therapeutics Inc (NASDAQ:TVRD) to $15.00 from $55.00 while maintaining a Buy rating following disappointing clinical trial results. According to InvestingPro data, four analysts have recently revised their earnings estimates downward, with price targets ranging from $42 to $78.
The price target reduction comes after preliminary results from the REVERT-IPF Phase 2 trial of Tvardi’s lead STAT3 inhibitor, TTI-101, in idiopathic pulmonary fibrosis (IPF) showed no discernible benefit on FVC decline compared to placebo.
The trial data revealed higher discontinuation rates for TTI-101, primarily attributed to gastrointestinal-related adverse events, with 57%-62% of patients on TTI-101 experiencing these side effects versus 10% for placebo.
BTIG removed TTI-101 in IPF from its financial model and raised its discount rate to 20.0% from 17.5%, reflecting increased risk in Tvardi’s pipeline.
Tvardi continues to advance TTI-109, a pro-drug of TTI-101 with improved bioavailability and potentially fewer gastrointestinal side effects, with preliminary healthy volunteer data expected in the first half of 2026, while a separate Phase 1b/2 trial of TTI-101 in hepatocellular carcinoma remains ongoing. Get access to 12 additional InvestingPro Tips and comprehensive financial analysis to better understand Tvardi’s investment potential.
In other recent news, Tvardi Therapeutics announced disappointing preliminary results from its Phase 2 REVERT trial evaluating TTI-101 in idiopathic pulmonary fibrosis (IPF). The trial, which involved 88 patients, did not meet its goals, leading to a significant impact on the company’s stock. Oppenheimer analyst Jay Olson responded by slashing the company’s price target from $65.00 to $10.00, though he maintained an Outperform rating. Meanwhile, Barclays initiated coverage on Tvardi Therapeutics with an Overweight rating and set a $61.00 price target, highlighting the company’s focus on developing therapeutics for fibrosis-driven diseases.
Additionally, Tvardi Therapeutics announced the resignation of Shaheen Wirk from its board of directors, effective July 8. The company clarified that Dr. Wirk’s decision to resign was not due to any disagreements. Dr. Wirk had joined the board in March 2024, having previously served as a special advisor. Tvardi expressed gratitude for his contributions during his tenure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.